#1 Clinical Trials Search in Europe

Ipilimumab

Ipilimumab, also known by its brand name Yervoy, is an immunotherapy drug being studied in various clinical trials for the treatment of different types of cancer, primarily melanoma. This article explores how ipilimumab is being used in clinical trials, its potential benefits, and what researchers are learning about its effects on the immune system and cancer treatment.

Table of Contents

What is IPILIMUMAB?

IPILIMUMAB is an immunotherapy drug used in the treatment of various types of cancer. It is also known by its brand name Yervoy[1]. IPILIMUMAB belongs to a class of drugs called immune checkpoint inhibitors, which help the body’s immune system fight cancer cells[2].

How Does IPILIMUMAB Work?

IPILIMUMAB works by targeting a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on the surface of immune cells. By blocking CTLA-4, IPILIMUMAB helps activate and increase the number of cancer-fighting T cells in the body. This enhanced immune response can help attack and destroy cancer cells[3].

What Cancers Does IPILIMUMAB Treat?

IPILIMUMAB has shown effectiveness in treating several types of cancer, including:

  • Melanoma: A type of skin cancer[1]
  • Colorectal cancer: Cancer of the colon or rectum[4]
  • Hepatocellular carcinoma (HCC): The most common type of liver cancer[5]
  • Urothelial cancer: Cancer that affects the urinary system[6]

It is also being studied for use in other cancer types and at different stages of disease progression.

How is IPILIMUMAB Administered?

IPILIMUMAB is typically given as an intravenous (IV) infusion, which means it is delivered directly into the bloodstream through a vein. The dosage and frequency of administration can vary depending on the specific treatment plan and type of cancer. Some common dosing schedules include:

  • Every 3 weeks for a total of 4 doses[7]
  • Every 6 or 8 weeks as part of a maintenance therapy[1]

In some clinical trials, researchers are also exploring the use of IPILIMUMAB as an intratumoral injection, where the drug is injected directly into the tumor[2].

IPILIMUMAB in Combination Therapies

IPILIMUMAB is often used in combination with other cancer treatments to enhance its effectiveness. Some common combination therapies include:

  • IPILIMUMAB + Nivolumab (another immunotherapy drug)[1]
  • IPILIMUMAB + Atezolizumab + Bevacizumab (for liver cancer)[5]
  • IPILIMUMAB + Temozolomide (a chemotherapy drug)[8]
  • IPILIMUMAB + Radiotherapy[9]

These combinations aim to attack cancer from multiple angles, potentially improving treatment outcomes.

Potential Side Effects

As with any medication, IPILIMUMAB can cause side effects. Because it works by stimulating the immune system, many of its side effects are related to an overactive immune response. Some potential side effects include:

  • Fatigue
  • Diarrhea
  • Skin rash or itching
  • Nausea
  • Fever
  • Inflammation in various organs (such as the liver, lungs, or intestines)[6]

It’s important to report any side effects to your healthcare team promptly, as they can often be managed effectively if caught early.

Ongoing Research and Future Directions

Researchers continue to study IPILIMUMAB to find new ways to use it effectively in cancer treatment. Some areas of ongoing research include:

  • Testing IPILIMUMAB in new cancer types and stages[10]
  • Exploring different dosing schedules and administration methods[2]
  • Investigating new combination therapies[5]
  • Identifying biomarkers that can predict which patients will respond best to the treatment[8]

These ongoing studies aim to improve the effectiveness of IPILIMUMAB and expand its use to help more cancer patients in the future.

Aspect Details
Main Cancer Types Studied Melanoma (including uveal melanoma), Prostate Cancer
Dosage Range 0.3 mg/kg to 10 mg/kg
Administration Method Intravenous infusion
Common Treatment Schedule Every 3 weeks for induction, followed by maintenance doses
Primary Outcomes Measured Overall response rate, safety profile, immune system effects
Secondary Outcomes Progression-free survival, overall survival, quality of life
Combination Therapies Studied with other immunotherapies (e.g., nivolumab) and novel treatments (e.g., Tumor Treating Fields)
Safety Considerations Monitoring for immune-related adverse events affecting various organ systems

FAQ

  • What is ipilimumab and how does it work? Ipilimumab is a monoclonal antibody that works by blocking CTLA4, a protein found on immune system cells. By blocking CTLA4, ipilimumab aims to stimulate the immune system to fight cancer cells more effectively.
  • What types of cancer is ipilimumab being studied for? While ipilimumab is FDA-approved for melanoma treatment, clinical trials are exploring its use in various cancers, including metastatic uveal melanoma and metastatic castration-resistant prostate cancer.
  • How is ipilimumab administered in clinical trials? In most trials, ipilimumab is administered intravenously, with doses ranging from 0.3 mg/kg to 10 mg/kg. The frequency of administration varies, but it's often given every 3 weeks for a set number of doses, followed by maintenance doses.
  • What are some potential side effects of ipilimumab? Common side effects include immune-related adverse events (irAEs) affecting various organ systems, such as the skin, gastrointestinal tract, liver, and endocrine system. The severity can range from mild to life-threatening, and careful monitoring is required.
  • What are researchers hoping to learn from these clinical trials? Researchers are studying ipilimumab's efficacy in different cancers, optimal dosing strategies, potential biomarkers for response prediction, its effects on the immune system, and its safety profile when used alone or in combination with other treatments.

Ongoing Clinical Trials on Ipilimumab

  • Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Nivolumab, Ipilimumab, and Myeloid Dendritic Cells for Patients with Recurrent Glioblastoma After Surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +4

  • Study on Melphalan, Ipilimumab, and Nivolumab for Patients with Uveal Melanoma Liver Metastases

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway Sweden

  • Study on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +4

  • Study on Immunotherapy with Atezolizumab, Tiragolumab, and Ipilimumab for Patients with Advanced Triple Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Immunotherapy with Nivolumab and Ipilimumab for Patients with Early Stage dMMR Rectal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

Glossary

  • Ipilimumab: A monoclonal antibody drug that works by blocking CTLA4, a protein that slows down the immune response. It's designed to stimulate the immune system to fight cancer cells.
  • CTLA4: Cytotoxic T Lymphocyte Antigen 4, a protein found on immune system cells that helps regulate immune responses.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. It's designed to target specific parts of cancer cells.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • Melanoma: A type of skin cancer that develops in cells called melanocytes, which produce the pigment that gives skin its color.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Uveal melanoma: A rare type of eye cancer that develops in the uvea, the pigmented layer of the eye.
  • Castration-resistant prostate cancer: Prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels.
  • Immune-related adverse events (irAEs): Side effects caused by the immune system attacking healthy cells in the body as a result of immunotherapy treatment.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.

References

  1. https://clinicaltrials.gov/study/NCT05926960
  2. https://clinicaltrials.gov/study/NCT02977156
  3. https://clinicaltrials.gov/study/NCT02307149
  4. https://clinicaltrials.gov/study/NCT03982121
  5. https://clinicaltrials.gov/study/NCT05665348
  6. https://clinicaltrials.gov/study/NCT05219435
  7. https://clinicaltrials.gov/study/NCT02662725
  8. https://clinicaltrials.gov/study/NCT03832621
  9. https://clinicaltrials.gov/study/NCT01497808
  10. https://clinicaltrials.gov/study/NCT05407441